HOME >> MEDICINE >> NEWS
Drug treatment before angioplasty or stent placement not beneficial for heart attack patients

A common practice for improving outcomes in patients with sudden heart attack actually offers no benefit and could cause harm, according to a review of randomised trials published online today (Tuesday February 14, 2006) by The Lancet.

Despite the lack of evidence for its safety and effectiveness, many doctors believe the practice of giving patients with sudden ST-elevation* heart attack drugs before undergoing emergency revascularisation procedures (angioplasty or stent placement**) improves outcome. However, preliminary studies have suggested this practice confers no benefit.

To investigate the effect of pre-intervention drug treatment, Ellen Keeley (University of Texas Southwestern Medical Center, Dallas, TX, USA) and colleagues reviewed data from 17 trials comparing the outcomes for ST-elevation heart attack patients assigned the drug based procedure before angioplasty/stent placement (2237) and those assigned angioplasty/stent placement alone (2267). The investigators found that more of the patients who received drugs prior to their intervention died than those who did not receive medication (106 versus 78). Pre-intervention drugs also increased the risk of non-fatal heart attack, bleeding, stroke, and the need for repeat revascularisation treatment. These increased rates were mainly seen when the pharmacological treatment was a drug that dissolved clots (thrombolytic therapy).

Dr Keeley states: "Drug facilitated angioplasty or stent placement offers no benefit over primary intervention in ST-elevation heart attack and should not be used outside the context of randomised controlled trials. Furthermore facilitated interventions with thrombolytic-based regimens should be avoided." (Quote by e-mail; not in paper)

In an accompanying Comment Drs. Gregg Stone (Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA) and Bernard Gersh (Mayo Clinic, Rochester, MN, USA) state: "The results of thi
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
13-Feb-2006


Page: 1 2

Related medicine news :

1. Spot on treatment for acne
2. New treatment boosts muscle function in myasthenia gravis
3. New treatment effective in counteracting cocaine-induced symptoms
4. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
5. Preventive treatments in elderly people needs rethinking
6. Osteoporosis screening and treatment may be cost-effective for selected older men
7. Quality of treatment guidelines
8. Green tea holds promise as new treatment for inflammatory skin diseases
9. Many heart attack patients still not getting emergency clot-busting treatment
10. Electric fields have potential as a cancer treatment
11. New algorithm matches any tumor cells to best possible anti-cancer treatments

Post Your Comments:
(Date:7/31/2014)... Women over the age of 65 face numerous barriers ... struggles against poverty and higher rates of asthma with ... issue of Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), outlines the challenges faced ... solutions to improve their care. , "Allergists ...
(Date:7/31/2014)... 2014 The 2013 PolyU TSI ... points from 75.07 in 2012. The index measures ... and integrates them into an overall index. The ... more satisfied with Hong Kong over time. , ... in service performance in Hong Kong are attractions ...
(Date:7/31/2014)... 2014 Ce-Classes.com has announced that they ... healthcare professionals, a Systematic Review of Sexual Satisfaction ... in the International Journal of Clinical and Health Psychology. ... to a need to have accurate information about sexual ... treatment possible. The material provides a systematic review ...
(Date:7/31/2014)... GA (PRWEB) July 31, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3
(Date:7/31/2014)... , July 31, 2014 Catylix, Inc. ... Scientific ( Milpitas, California ) announced ... develop and commercialize new fluorination products and related ... has benefited from the use of substituents that ... lipophilicity with polarity to improve binding and bioavailability. ...
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company ... conference call on Thursday, August 14, 2014, at 4:30 p.m. ... June 30, 2014. Financial results will be issued in a ... President and CEO James LaFrance will host the ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
Cached News: